Identifying Early Biomarkers in Olfactory Mucosa, Blood, and Urine to Improve Diagnosis of Parkinsons Disease, Multiple System Atrophy, and Lewy Body Dementia

What this Trial Is About

Researchers are exploring early biomarkers in the olfactory mucosa, blood, and urine to improve diagnosis of Parkinsons disease PD, multiple system atrophy MSA, and dementia with Lewy bodies DLB. These diseases are linked to misfolded alpha-synuclein proteins that form aggregates in the brain, which are key diagnostic markers. The study combines expertise in neurology, molecular biology, biophysics, and machine learning to analyze these biomarkers for better disease recognition. The study uses advanced and ultrasensitive tests such as RT-QuIC, Simoa SR-X, ELISA, and NTA on samples of olfactory mucosa, blood, and urine from patients with PD, MSA, and DLB. Techniques like transmission electron microscopy TEM and nuclear magnetic resonance NMR will characterize protein aggregates. Machine learning will combine clinical and experimental data to identify specific patterns that could distinguish these diseases. Participants will provide easily collectible samples like olfactory mucosa, blood, and urine periodically for up to three years. Researchers will assess olfactory function and analyze biomarkers to develop predictive models for diagnosis. The study includes safety monitoring and aims to enable ongoing disease monitoring and evaluation of treatment effects. The total study duration is three years, with multiple assessments and advanced laboratory analyses conducted over this period.

Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease